Mouse Anti-DHX32 Recombinant Antibody (2G4) (V2LY-0425-LY290)

Wei, Q., Geng, J., Chen, Y., Lin, H., Wang, J., Fang, Z., ... & Zhang, Z. (2021). Structure and function of DEAH-box helicase 32 and its role in cancer. Oncology Letters, 21(5), 1-8.

Hu, X., Yuan, G., Li, Q., Huang, J., Cheng, X., & Chen, J. (2021). DEAH-box polypeptide 32 promotes hepatocellular carcinoma progression via activating the β-catenin pathway. Annals of Medicine, 53(1), 437-447.

Cai, M. J., Zhu, J. H., He, J. Q., Zhang, Z. Y., & Liang, X. M. (2020). Silencing of DHX32 increases the proliferation of liver cancer cells. TRANSLATIONAL CANCER RESEARCH, 9(3), 1833-1842.

Wang, M., Zhang, G., Wang, Y., Ma, R., Zhang, L., Lv, H., ... & Kang, X. (2017). DHX32 expression is an indicator of poor breast cancer prognosis. Oncology letters, 13(2), 942-948.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols